BioMarin Announces that Phase 3 Cohort of Valoctocogene Roxaparvovec, Gene Therapy Study in Severe Hemophilia A Met Pre-Specified Criteria for Regulatory Submissions in the U.S. and Europe

Author's Avatar
May 28, 2019
Article's Main Image

Timing of Regulatory Submissions to Be Determined in 3Q 2019

Conference Call and Webcast to be Held Tuesday, May 28, 2019 at 8:00 AM Eastern

PR Newswire